MediPharm Labs Sets Date to Release Full Year 2019 and Fourth Quarter Financial Results
February 13 2020 - 7:00AM
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ)
(“MediPharm Labs” or the “Company”) a global leader in
research-driven, pharmaceutical quality cannabis extraction,
distillation and derivative product production, announced it will
release its audited financial results, within the timelines
required by TSX issuers, for the three and twelve months ended
December 31, 2019 before markets open on Monday, March 30, 2020.
The Company’s management team will also host a
conference call and audio webcast on Monday, March 30, 2020 at 8:30
a.m. eastern time to discuss its results and outlook.
Conference Call
Information:
Toll-free number: 877-791-0216 / International
number: 647-689-5661 / Conference ID: 5576297
Participants are asked to dial in approximately
10 minutes before the start of the call.
Audio Webcast:
An audio webcast will be available in the Events
section of the MediPharm Labs’ Investor Relations website
https://ir.medipharmlabs.com/news-events or by visiting the
following link:
https://event.on24.com/wcc/r/2152211/3D5EEC47DD1A08B3183F90AD781074FE
For those who are unable to participate on the
live conference call and webcast, a replay will be available
approximately one hour after completion of the call.
Replay Information:
Replay number: 800-585-8367 / International
replay number: 416-621-4642 / Conference ID: 5576297
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in
the production of purified, pharmaceutical quality cannabis oil and
concentrates and advanced derivative products utilizing a Good
Manufacturing Practices certified facility and ISO standard built
clean rooms. MediPharm Labs has invested in an expert, research
driven team, state-of-the-art technology, downstream purification
methodologies and purpose-built facilities with five primary
extraction lines for delivery of pure, trusted and precision-dosed
cannabis products for its customers. Through its wholesale and
white label platforms, MediPharm Labs formulates, sensory-tests,
processes, packages and distributes cannabis extracts and advanced
cannabinoid-based products to domestic and international markets.
As a global leader, MediPharm Labs has completed commercial exports
to Australia and is nearing commercialization of its Australian
extraction facility. MediPharm Labs Australia was established in
2017.
For further information, please contact: Laura
Lepore, VP, Investor Relations Telephone: 416-913-7425 ext 1525
Email: investors@medipharmlabs.com Website:
www.medipharmlabs.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
INFORMATION:
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking statements”) within the meaning of the applicable
Canadian securities legislation. All statements, other than
statements of historical fact, are forward-looking statements and
are based on expectations, estimates and projections as at the date
of this news release. Any statement that involves discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, assumptions, future events or performance (often but
not always using phrases such as “expects”, or “does not expect”,
“is expected”, “anticipates” or “does not anticipate”, “plans”,
“budget”, “scheduled”, “forecasts”, “estimates”, “believes” or
“intends” or variations of such words and phrases or stating that
certain actions, events or results “may” or “could”, “would”,
“might” or “will” be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements relate
to, among other things, the completion of the Australian facility.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties, and other
factors which may cause the actual results and future events to
differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; the inability of MediPharm Labs to obtain
adequate financing; the delay or failure to receive regulatory
approvals; and other factors discussed in MediPharm Labs’ filings,
available on the SEDAR website at www.sedar.com. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on the forward-looking statements and
information contained in this news release. Except as required by
law, MediPharm Labs assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change.
VIVO Cannabis (TSX:LABS)
Historical Stock Chart
From Mar 2024 to Apr 2024
VIVO Cannabis (TSX:LABS)
Historical Stock Chart
From Apr 2023 to Apr 2024